Induction of Donor Tolerance in Renal Transplants

肾移植中诱导供体耐受

基本信息

  • 批准号:
    8333414
  • 负责人:
  • 金额:
    $ 173.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-06-03 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Renal transplantation is the preferred therapeutic approach for end organ failure. However, the chronic use of immunosuppressive agents is critical to prevent rejection. The drugs are costly ($15,000-25,000/year) and have significant toxicities including opportunistic infection, an increased rate of malignancy, nephrotoxicity, and other end organ damage. The induction of donor-specific tolerance would address these limitations. Bone marrow chimerism induces tolerance to transplanted organs. However, the toxicity and complications associated with conventional hematopoietic stem cell transplants (HSCT), primarily graft-versus-host disease (GVHD) and the need for a matched donor, has limited the therapeutic application of HSCT to tolerance induction. We have identified and patented a novel tolerogenic bone marrow cell population of CD8+/TCR- facilitating cells (FC) that enhances engraftment of stem cells in mismatched recipients without causing GVHD. The discovery of FC opens the door to employing HSCT as a viable cell-based approach for tolerance induction. The product, FCRx, addresses the major challenges preventing the widespread use of HSCT for tolerance induction. FCRx is a bioengineered bone marrow product that includes hematopoietic stem cells (HSC) and FC, but avoids GVHD in mismatched recipients. In phase I of this proposal, we achieved our proposed milestones, demonstrating that we could reliably produce and transport FCRx and safely infuse it into nonmyeloablatively conditioned renal transplant recipients. We demonstrated that the proprietary FCRx procedure can routinely produce a graft with defined 12-TCR+ T cell composition and enriched for HSC and engraftment-enhancing FC. The ultimate goal is the induction of immune tolerance and the elimination of or reduction in the need for expensive and harmful immunosuppressive drugs. We have developed a nonmyeloablative conditioning regimen with 200 cGy TBI/fludarabine/cyclophosphamide/MMF/prograf to avoid the toxicity of conditioning. Since completing Phase I, we have addressed a major concern expressed by the reviewers regarding our ability to enroll subjects and have now successfully transplanted 6 living donor kidney patients, all of whom demonstrated donor chimerism at one month post-transplant. The approaches for collection, shipping, and FCRx preparation have also been approved by the FDA. Three patients show laboratory evidence of donor-specific tolerance, and immunosuppression is being weaned. The remaining subjects are early in follow-up. The reproducibility and quality assurance of the FCRx process will lead to its successful commercial launch. In phase II we will increase the pace of transplants and demonstrate that FCRx consistently achieves engraftment of HLA mismatched HSC in nonmyeloablatively conditioned kidney transplant recipients, induces donor-specific tolerance without causing significant GVHD, and reduces or eliminates the need for long-term immunosuppression. A recent meeting with FDA classified our product as Phase II, another milestone that will enhance commercialization.
描述:肾移植是终末器官衰竭的首选治疗方法。然而,长期使用免疫抑制剂对预防排斥反应至关重要。这些药物价格昂贵(15,000 - 25,000美元/年),并且具有显著的毒性,包括机会性感染、恶性肿瘤发生率增加、肾毒性和其他终末器官损伤。诱导供体特异性耐受将解决这些局限性。骨髓嵌合体诱导移植器官耐受。然而,与常规造血干细胞移植(HSCT)相关的毒性和并发症,主要是移植物抗宿主病(GVHD)和对匹配供体的需要,限制了HSCT在耐受诱导方面的治疗应用。我们已经鉴定了一种新型的致耐受性骨髓细胞群CD 8 +/TCR-促进细胞(FC),并获得专利,该细胞群可增强干细胞在不匹配受体中的植入,而不会引起GVHD。FC的发现为采用HSCT作为基于活细胞的耐受诱导方法打开了大门。该产品FCRx解决了阻止广泛使用HSCT诱导耐受的主要挑战。FCRx是一种生物工程骨髓产品,包括造血干细胞(HSC)和FC,但在不匹配的受体中避免GVHD。在该提案的第一阶段,我们实现了我们提出的里程碑,证明我们可以可靠地生产和运输FCRx,并将其安全地输注到非清髓性条件性肾移植受者中。我们证明了专有的FCRx程序可以常规地产生具有确定的12-TCR+ T细胞组成的移植物,并且富含HSC和增强植入的FC。最终目标是诱导免疫耐受,消除或减少对昂贵和有害的免疫抑制药物的需求。我们开发了一种非清髓性预处理方案,采用200 cGy TBI/氟达拉滨/环磷酰胺/MMF/BMF,以避免预处理的毒性。自完成I期研究以来,我们已经解决了评审员对我们招募受试者能力的主要担忧,目前已成功移植了6例活体供肾患者,所有患者均在移植后1个月表现出供体嵌合体。用于收集、运输和FCRx制备的方法也已获得FDA批准。3例患者显示供者特异性耐受的实验室证据,免疫抑制正在解除。其余受试者处于早期随访中。FCRx工艺的重现性和质量保证将使其成功商业化。在第二阶段,我们将加快移植的速度,并证明FCRx在非清髓性条件肾移植受者中始终实现HLA不匹配的HSC的植入,诱导供体特异性耐受而不引起显著的GVHD,并减少或消除对长期免疫抑制的需要。最近与FDA的一次会议将我们的产品归类为II期,这是另一个将促进商业化的里程碑。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUZANNE T ILDSTAD其他文献

SUZANNE T ILDSTAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUZANNE T ILDSTAD', 18)}}的其他基金

Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients
与生活相关的供体肾移植受者的延迟耐受诱导
  • 批准号:
    8252790
  • 财政年份:
    2012
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    8003242
  • 财政年份:
    2010
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    7488881
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Induction of Donor Tolerance in Renal Transplants
肾移植中诱导供体耐受
  • 批准号:
    8058450
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
AMD-FCRx to Restore Damaged Pigment Epithelium
AMD-FCRx 可恢复受损的色素上皮
  • 批准号:
    6991727
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    6970186
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    7279886
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    7674545
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Tolerance Induction to Islet Transplants
胰岛移植耐受诱导
  • 批准号:
    7113228
  • 财政年份:
    2005
  • 资助金额:
    $ 173.34万
  • 项目类别:
Training Program in Transplantation
移植培训计划
  • 批准号:
    8500419
  • 财政年份:
    2004
  • 资助金额:
    $ 173.34万
  • 项目类别:

相似海外基金

Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 173.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10722602
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10368246
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
Eltombopag: Novel Mode of Action on Normal and Aplastic Anemia Hematopoietic Stem Cells
Eltombopag:对正常和再生障碍性贫血造血干细胞的新作用模式
  • 批准号:
    10676888
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10600143
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
  • 批准号:
    10347646
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10370775
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
The effects of somatic HLA class I allele mutations on antigen presentation in acquired aplastic anemia
体细胞 HLA I 类等位基因突变对获得性再生障碍性贫血抗原呈递的影响
  • 批准号:
    10545024
  • 财政年份:
    2022
  • 资助金额:
    $ 173.34万
  • 项目类别:
Identification of autoantigens presented by specific HLA class I alleles in aplastic anemia
再生障碍性贫血中特定 HLA I 类等位基因呈现的自身抗原的鉴定
  • 批准号:
    19H03686
  • 财政年份:
    2019
  • 资助金额:
    $ 173.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of novel genes related to aplastic anemia using mouse models.
使用小鼠模型对与再生障碍性贫血相关的新基因进行功能分析。
  • 批准号:
    19K08297
  • 财政年份:
    2019
  • 资助金额:
    $ 173.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了